Datapoint: Actemra Granted EUA for Use in COVID Patients

The FDA last week granted Roche’s Actemra an emergency use authorization to treat both adult and juvenile patients hospitalized with COVID-19. The arthritis drug was previously approved for compassionate use, but can now be administered to COVID patients who require oxygen support, in tandem with corticosteroids. For the treatment of rheumatoid arthritis, the intravenous form of Actemra holds covered or better status for 93% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/28/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 24

Datapoint: FDA Approves Alvotech and Teva’s Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 23

Datapoint: Elevance to Take On Primary Care Expansion

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 18

Datapoint: FDA Delays New Leqembi Launch

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today